Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
PELTHOS THERAPEUTICSEli Lilly
Last price
$19.59$1,306.69
Currency
USD
USD
$75M$1.1T
-42.66
-$26.36$29.79
3.130.45
0$6.69
00.54%
Sector
HealthHealth
Employees
9250,000
Ticker
$PTHS$LLY
Primary listing
AMEXNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $PTHS or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.